000 02294nam a22003377a 4500
008 221018s20222022 xxu||||| |||| 00| 0 eng d
022 _a2471-254X
024 _a10.1002/hep4.2094 [doi]
040 _aOvid MEDLINE(R)
099 _a36166191
245 _aApproach to the patient with decompensated cirrhosis and aortic stenosis during liver transplantation evaluation. [Review]
251 _aHepatology Communications. 2022 Sep 27
252 _aHepatol. commun.. 2022 Sep 27
253 _aHepatology communications
260 _c2022
260 _fFY2023
260 _p2022 Sep 27
265 _saheadofprint
266 _d2022-10-20
520 _aAortic stenosis (AS) is the most common valvular disease and is reported to be present in 2%-7% of people over the age of 65. Risk factors for aortic stenosis and NASH overlap; thus, as the population ages, there is an increased likelihood that patients undergoing liver transplantation evaluation may have severe aortic stenosis. There is a high mortality rate associated with cardiac surgeries in patients with cirrhosis. Further, there are no guidelines that assist in the decision making process for patients with cirrhosis and AS. In this review, we highlight key studies that compare transcatheter aortic valve implantation (TAVI) with surgical aortic valve replacement (SAVR) in patients with cirrhosis. We propose an algorithm as to how to approach the patient with aortic stenosis and considerations unique to patients with cirrhosis (i.e., anticoagulation, EGD for variceal assessment; need to determine timing after TAVI before listing). Copyright © 2022 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
546 _aEnglish
650 _aIN PROCESS -- NOT YET INDEXED
656 _aMedStar Georgetown University Hospital/MedStar Washington Hospital Center
656 _aTransplant Hepatology Fellowship
657 _aJournal Article
657 _aReview
700 _aNguyen, Veronica
_bMGUH
_cTransplant Hepatology Fellowship
_dMD
_eAlumni
790 _aDe Marchi L, Duong N, Nguyen V, Thomas A
856 _uhttps://dx.doi.org/10.1002/hep4.2094
_zhttps://dx.doi.org/10.1002/hep4.2094
942 _cART
_dArticle
999 _c282
_d282